Results 261 to 270 of about 3,307,905 (304)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 2019
Cancer vaccines are a promising strategic approach within the rapidly growing field of immuno-oncology. Therapeutic cancer vaccines are distinct from prophylactic vaccines and vary by both target antigen and vaccine platform. There are currently 3 FDA-approved therapeutic cancer vaccines: intravesical BCG live, sipuleucel-T, and T-VEC.
Peter J, DeMaria, Marijo, Bilusic
openaire +2 more sources
Cancer vaccines are a promising strategic approach within the rapidly growing field of immuno-oncology. Therapeutic cancer vaccines are distinct from prophylactic vaccines and vary by both target antigen and vaccine platform. There are currently 3 FDA-approved therapeutic cancer vaccines: intravesical BCG live, sipuleucel-T, and T-VEC.
Peter J, DeMaria, Marijo, Bilusic
openaire +2 more sources
Expert Opinion on Therapeutic Targets, 2004
Cancer vaccines - a dream or a reality? There is no doubt that a time will come when this new approach to cancer treatment will provide opportunities that will be both complementary and synergistic with existing treatments. Novelty is often linked to risk, and if there is a given medical field that desperately needs therapeutic improvement, cancer is ...
openaire +2 more sources
Cancer vaccines - a dream or a reality? There is no doubt that a time will come when this new approach to cancer treatment will provide opportunities that will be both complementary and synergistic with existing treatments. Novelty is often linked to risk, and if there is a given medical field that desperately needs therapeutic improvement, cancer is ...
openaire +2 more sources
2012 Sixth International Conference on Complex, Intelligent, and Software Intensive Systems, 2012
Cancer vaccine research is a hot topic for medical treatments of cancer. Identification of candidate antigenic stimuli for the vaccine is already improved using immune-informatics. Subsequent test in vivo are expensive and time consuming. There is an increasing request to a modeling approach to speed up this phase of vaccine research.
Francesco Pappalardo 0001, Santo Motta
openaire +3 more sources
Cancer vaccine research is a hot topic for medical treatments of cancer. Identification of candidate antigenic stimuli for the vaccine is already improved using immune-informatics. Subsequent test in vivo are expensive and time consuming. There is an increasing request to a modeling approach to speed up this phase of vaccine research.
Francesco Pappalardo 0001, Santo Motta
openaire +3 more sources
Nanodevices for cancer vaccination
Nature Materials, 2021An elaborate DNA origami tubular nanodevice encapsulating antigens and adjuvants protects mice from cancer through tumour-specific immunomodulation.
Hongjun Li, Zhen Gu
openaire +2 more sources
The Cancer Journal, 2003
Human papillomaviruses (HPVs) are responsible for the nearly 450,000 cervical cancers that occur each year throughout the world. In the United States, the cancer rate is low (13,500 cases per year); nevertheless, HPVs affect millions of men and women annually in the form of genital warts and preinvasive diseases of the cervix and anogenital region. The
Christopher P, Crum, Miguel N, Rivera
openaire +2 more sources
Human papillomaviruses (HPVs) are responsible for the nearly 450,000 cervical cancers that occur each year throughout the world. In the United States, the cancer rate is low (13,500 cases per year); nevertheless, HPVs affect millions of men and women annually in the form of genital warts and preinvasive diseases of the cervix and anogenital region. The
Christopher P, Crum, Miguel N, Rivera
openaire +2 more sources
Current Gene Therapy, 2007
Cytotoxic chemotherapy is associated with modest survival advantage as initial treatment of advanced lung cancer. However, toxicity and minimal benefit to use second line treatment justifies exploration of alternative approaches. Recent understanding of mechanisms by which tumor antigen recognition can be enhanced has justified development of a recent ...
Rob, Eager +2 more
openaire +2 more sources
Cytotoxic chemotherapy is associated with modest survival advantage as initial treatment of advanced lung cancer. However, toxicity and minimal benefit to use second line treatment justifies exploration of alternative approaches. Recent understanding of mechanisms by which tumor antigen recognition can be enhanced has justified development of a recent ...
Rob, Eager +2 more
openaire +2 more sources
Surgical Oncology Clinics of North America, 2007
Therapeutic cancer vaccines target the cellular arm of the immune system to initiate a cytotoxic T-lymphocyte response against tumor-associated antigens. Immunotherapy offers one of the few therapeutic options that reproducibly leads to a subset of patients with long-term remissions (seemingly cures) of widely metastatic disease.
Lilah F, Morris, Antoni, Ribas
openaire +2 more sources
Therapeutic cancer vaccines target the cellular arm of the immune system to initiate a cytotoxic T-lymphocyte response against tumor-associated antigens. Immunotherapy offers one of the few therapeutic options that reproducibly leads to a subset of patients with long-term remissions (seemingly cures) of widely metastatic disease.
Lilah F, Morris, Antoni, Ribas
openaire +2 more sources
Expert Opinion on Therapeutic Patents, 2001
The intellectual property literature concerning novel cancer vaccine strategies for the period of 1998 and 2000 is reviewed. Nearly 400 citations have been identified and the majority of the citations described herein involve the identification of new tumour associated antigens and novel strategies of cancer vaccine formulations. Significant progresses
openaire +2 more sources
The intellectual property literature concerning novel cancer vaccine strategies for the period of 1998 and 2000 is reviewed. Nearly 400 citations have been identified and the majority of the citations described herein involve the identification of new tumour associated antigens and novel strategies of cancer vaccine formulations. Significant progresses
openaire +2 more sources
2014
Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain.
Hauke, Winter +2 more
openaire +2 more sources
Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain.
Hauke, Winter +2 more
openaire +2 more sources
Trends in Molecular Medicine, 2002
The application of 'new' and 'recognized' tumour antigens in vaccination strategies that target CD8(+) and CD4(+) T-cell responses, and the mechanisms by which these and other effector cells are activated or respond, were discussed at the second 'Progress in Vaccination Against Cancer' meeting, held at the Nottingham Trent Djanogly Conference Centre ...
Graham, Pawelec, Robert C, Rees
openaire +2 more sources
The application of 'new' and 'recognized' tumour antigens in vaccination strategies that target CD8(+) and CD4(+) T-cell responses, and the mechanisms by which these and other effector cells are activated or respond, were discussed at the second 'Progress in Vaccination Against Cancer' meeting, held at the Nottingham Trent Djanogly Conference Centre ...
Graham, Pawelec, Robert C, Rees
openaire +2 more sources